

CITATION REPORT

List of articles citing

European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

DOI: 10.1097/01.hjr.0000277984.31558.c4

European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14 Suppl 2, E1-40.

Source: <https://exaly.com/paper-pdf/42203067/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
328	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. 2008 , 24, 645-71		75
327	Atherosclerotic cardiovascular diseases in Belgium: a cost-of-illness analysis. 2008 , 22, 487-94		9
326	Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. 2008 , 2, 128-37		31
325	[Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP)]. 2008 , 120, 558-65		7
324	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. 2008 , 18, 2785-807		78
323	Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke. 2008 , 3, 237-48		13
322	Vitalum study design: RCT evaluating the efficacy of tailored print communication and telephone motivational interviewing on multiple health behaviors. 2008 , 8, 216		27
321	Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. 2008 , 2, 343-53		4
320	Health service interventions targeting relatives of heart patients: a review of the literature. 2008 , 36, 818-26		8
319	Commentary: The six biological inventions in Haldane's Daedalus. 2008 , 37, 454-69		0
318	Heartscore calculated in individuals younger than 40 years is related to vascular markers of early atherosclerosis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008 , 15, 619-24		3
317	European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces. 2008 , 26, 157-60		3
316	Effects of a home-based cardiac rehabilitation program on the physical activity levels of patients with coronary artery disease. 2008 , 28, 392-6		30
315	Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients. 2009 , 6, 2800-11		1
314	Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. 2009 , 25, 2817-28		8
313	Ethnic differences in SCORE cardiovascular risk in Oslo, Norway. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 229-34		33
312	Handgrip strength as a predictor of prognosis in Japanese patients with congestive heart failure. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 21-7		71

311	How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 304-14	92
310	EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 121-37	536
309	National Coordinators: an active network dedicated to CVD prevention. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S55-7	
308	A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 712-21	15
307	Vigorous physical activity and vagal modulation in young adults. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 705-11	23
306	Homocysteine increases the risk associated with hyperlipidaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 150-5	20
305	High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. 2009 , 30, 1894-902	29
304	Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. 2009 , 121, 44-53	8
303	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 404-23	42
302	Call for action: to promote a heart-healthy environment in Europe. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S53-4	1
301	Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 562-70	28
300	Evaluating the causal relevance of diverse risk markers: horizontal systematic review. 2009 , 339, b4265	37
299	Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. 2009 , 32, 2094-8	76
298	Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 39-46	45
297	Practical organisation of preventive cardiology programmes: integrating prevention and rehabilitation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S37-42	3
296	The challenge for preventive cardiology. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S19-23	3
295	What is my risk of developing cardiovascular disease?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16 Suppl 2, S2-7	3
294	Association of physicians' accuracy in recording with quality of care in cardiovascular medicine. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 722-8	17

293	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. 2009 , 27, 2121-58	1004
292	Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 541-9	77
291	Relative importance and conjoint effects of obesity and physical inactivity for the development of insulin resistance. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 28-33	14
290	Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients. 2009 , 9, 17	5
289	Effects of selective I f-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy. 2009 , 98, 681-4	4
288	Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?. 2009 , 26, 469-87	13
287	Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). 2009 , 52, 218-25	22
286	Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. 2009 , 52, 415-24	114
285	ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. 2009 , 10, 50	23
284	Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. 2009 , 67, 355-62	21
283	Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. 2009 , 54, 1209-27	267
282	Cardiovascular disease and diabetes in people with severe mental illness. 2009 , 2, 49-59	15
281	Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. 2009 , 69, 1077-105	32
280	Cardiac rehabilitation in Austria: long term health-related quality of life outcomes. 2009 , 7, 99	13
279	Metabolic syndrome in people with schizophrenia: a review. 2009 , 8, 15-22	383
278	SCORE should be preferred to Framingham to predict cardiovascular death in French population. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 609-15	12
277	Protocolo de tratamiento de las dislipidemias aterogénicas. 2009 , 10, 2737-2741	
276	Ergo-anthropometric Assessment. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 940-941	6.4

275	The effect of cardiac rehabilitation with relaxation therapy on psychological, hemodynamic, and hospital admission outcome variables. 2009 , 29, 304-9	15
274	Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. 2010 , 60, 884-90	31
273	Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 562-8	4
272	Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 569-75	58
271	[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society]. 2010 , 81, 444-62	12
270	Trends in age-standardised and age-specific mortality from ischaemic heart disease in Germany. 2010 , 99, 545-51	10
269	[ProCor: an extramural screening on heart rate reduction in patients with chronic stable angina pectoris in Austria]. 2010 , 122, 486-93	1
268	Extracellular heat shock protein 70 (HSPA1A) and classical vascular risk factors in a general population. 2010 , 15, 929-37	42
267	Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals. 2010 , 33, 244-50	7
266	Prevenci3 secundaria en enfermedad cardiovascular. 2010 , 17, 5-41	
265	Type D personality is associated with increased metabolic syndrome prevalence and an unhealthy lifestyle in a cross-sectional Dutch community sample. 2010 , 10, 714	65
264	The Viborg Vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: study protocol. 2010 , 11, 67	49
263	Gender-specific aspects in the clinical presentation of cardiovascular disease. 2010 , 24, 711-7	26
262	Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. 2010 , 64, 1765-72	3
261	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. 2010 , 34, 1255-64	84
260	Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. 2010 , 12, 210-8	28
259	Omega-3 Index and sudden cardiac death. 2010 , 2, 375-88	17
258	Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. 2010 , 6, 525-39	36

257	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. 2010 , 3, 79-96		6
256	Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. <i>World Journal of Gastroenterology</i> , 2010 , 16, 1943-52	5.6	46
255	Views on treatment necessity, harm, and benefits in patients using statins. 2010 , 30, 594-609		5
254	Lipoprotein(a) as a cardiovascular risk factor: current status. 2010 , 31, 2844-53		1100
253	Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs--the CEPHEUS-Greece survey. 2010 , 61, 465-74		16
252	Educational implementation programme of guidelines on cardiovascular risk factors: an analysis of changes in familiarity, use and attitudes. 2010 , 11, 241-249		4
251	Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 363-72		8
250	Effectiveness of nonpharmacological secondary prevention of coronary heart disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 688-700		40
249	Does the progeny of premature ischemic stroke sufferers need intensive interest of physicians oriented toward primary prevention? A pilot study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 725-9		
248	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 530-40		155
247	Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 140-54		33
246	Why patients should be more empowered: a European perspective on lessons learned in the management of diabetes. 2010 , 4, 1570-3		29
245	Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). 2010 , 31, 2041-8		158
244	Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden. 2010 , 26, 389-96		4
243	KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010 , 17, 455-61		61
242	Maladie cardiovasculaire et diab�e chez les personnes atteintes d'une maladie mentale s�re. 2010 , 4, 223-230		1
241	Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. 2010 , 56, 2006-20		177
240	Management of physical health in patients with schizophrenia: practical recommendations. 2010 , 25 Suppl 2, S41-5		26

- 239 Effects of cardiac rehabilitation referral strategies on referral and enrollment rates. **2010**, 7, 87-96 101
- 238 Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. **2010**, 9, 127 4
- 237 Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2010**, 17, 1-17 502
- 236 Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. **2010**, 26, 30-9 16
- 235 Pulse wave velocity: a marker of arterial stiffness and its applicability in clinical practice. **2011**, 30, 699-702 3
- 234 Aortic stiffness: current understanding and future directions. **2011**, 57, 1511-22 595
- 233 On-clopidogrel platelet reactivity: a target in sight?. **2011**, 58, 1955-7
- 232 [Pulse wave velocity: a marker of arterial stiffness and its applicability in clinical practice]. **2011**, 30, 699-702 3
- 231 Rationale and design for a cardiovascular screening and prevention study with tele-cardiology in Mediterranean Italy: the CAPITAL study (CArdiovascular Prevention wIth Telecardiology in ApuLia). **2011**, 149, 130-3 11
- 230 [Stagnant cardiovascular prevention: professional barriers]. **2011**, 64, 346-7; author reply 347
- 229 Stagnant Cardiovascular Prevention: Professional Barriers. **2011**, 64, 346-347
- 228 Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. **2011**, 7, 767-75 9
- 227 Vascular compliance in blood pressure. **2011**, 20, 457-64 21
- 226 The global burden of cardiovascular disease. **2011**, 26, S5-14 48
- 225 Does Carotid Intima-Media Thickness Regression Predict Reduction of Cardiovascular Events? A Meta-Analysis of 41 Randomized Trials. **2011**, 2011, 52-54
- 224 Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. **2011**, 11, 72-80 16
- 223 Quality of diabetes care in Austrian diabetic patients willing to participate in a DMP - at baseline. **2011**, 123, 436-43 7
- 222 Heart rate reduction in cardiovascular disease and therapy. **2011**, 100, 11-9 76

221	The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease. 2011 , 26, 457-63	8
220	Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. 2011 , 2, 15-26	11
219	The Heinz Nixdorf Recall study and its potential impact on the adoption of atherosclerosis imaging in European primary prevention guidelines. 2011 , 13, 367-72	15
218	The effect of regular walks on various health aspects in older people with dementia: protocol of a randomized-controlled trial. 2011 , 11, 38	12
217	Peripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk study. 2011 , 11, 266	16
216	Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. 2011 , 10, 7	35
215	Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. 2011 , 10, 82	11
214	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. 2011 , 44, 627-34	2
213	Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 97-105	24
212	Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 86-96	53
211	Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 287-96	13
210	Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. 2011 , 123, 1377-83	160
209	Direct renin inhibition: update on clinical investigations with aliskiren. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 424-37	0
208	Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. 2011 , 8, 160-72	15
207	Long-term effects of an expanded cardiac rehabilitation programme after myocardial infarction or coronary artery bypass surgery: a five-year follow-up of a randomized controlled study. 2011 , 25, 79-87	31
206	NT-proBNP and cardiac events in older diabetic patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 399-405	2
205	Belgian global implementation of cardiovascular and stroke risk assessment study: methods and baseline data of the BELGICA-STROKE STUDY. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 635-41	2
204	Self-reported physical inactivity predicts survival after hospitalization for heart disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 475-80	7

203	Long-term risk factor management after inpatient cardiac rehabilitation by means of a structured post-care programme. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 843-9	5
202	Predisease: when does it make sense?. 2011 , 33, 122-34	32
201	The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. 2011 , 1, e000363	25
200	Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 731-42	85
199	Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. 2011 , 70, 482-7	320
198	Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011 , 18, 270-7	24
197	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. 2011 , 52, 566-75	21
196	Pitavastatin: finding its place in therapy. 2011 , 2, 101-17	9
195	Population-wide use of behavioural prevention and counselling programmes for lifestyle-related cardiovascular risk factors in Germany. 2012 , 19, 849-56	5
194	Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. 2012 , 63, 184-93	13
193	Detection of bioprosthetic valve infection by image fusion of (18)fluorodeoxyglucose-positron emission tomography and computed tomography. 2012 , 14, 364-6	11
192	Why Do We Still Need Large Scale Clinical Trial: The Case of n-3 PUFA. 2012 , 3, 202	2
191	Some aspects of preventing coronary heart disease. 2012 , 63, 17-23	4
190	A systematic review on the application of cardiovascular risk prediction models in pharmacoconomics, with a focus on primary prevention. 2012 , 19, 42-53	4
189	Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. 2012 , 19, 541-50	74
188	Dietary energy density: a mediator of depressive symptoms and abdominal obesity or independent predictor of abdominal obesity?. 2012 , 11, 423-31	13
187	How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. 2012 , 9, 274-81	46
186	Management of noncardiac chest pain in women. 2012 , 8, 131-43; quiz 144-5	2

185	Implementation, target population, compliance and barriers to risk guided therapy. 2012 , 19, 37-41	6
184	Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. 2012 , 19, 43-54	8
183	Butyrylcholinesterase activity predicts long-term survival in patients with coronary artery disease. 2012 , 58, 1055-8	21
182	Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. 2012 , 19, 322-9	11
181	Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. 2012 , 19, 781-94	51
180	Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. 2012 , 6, 17-33	61
179	Impaired exercise tolerance is associated with increased urine albumin excretion in the early stages of essential hypertension. 2012 , 19, 452-9	2
178	Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. 2012 , 105, 11-27	13
177	Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. 2012 , 19, 1454-64	17
176	Fixed-dose combination therapy for the prevention of cardiovascular disease. 2012 ,	1
175	Arterial stiffness is increased in patients with inflammatory bowel disease. 2012 , 30, 1775-81	71
174	Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians' survey in China. 2012 , 19, 991-8	9
173	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). 2012 , 19, 585-667	233
172	E-Rehabilitation - an Internet and mobile phone based tailored intervention to enhance self-management of cardiovascular disease: study protocol for a randomized controlled trial. 2012 , 12, 50	23
171	Applicability of the ankle-brachial-index measurement as screening device for high cardiovascular risk: an observational study. 2012 , 12, 59	11
170	Critical review: vegetables and fruit in the prevention of chronic diseases. 2012 , 51, 637-63	1066
169	Coronary artery disease in Africa and the Middle East. 2012 , 8, 65-72	59
168	Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. 2012 , 3, 1-9	5

167	The perception and knowledge of cardiovascular risk factors among medical students. 2012 , 53, 278-84	23
166	Balcova heart study: rationale and methodology of the Turkish cohort. 2012 , 57, 535-42	22
165	Long-Term BMI changes since adolescence and markers of early and advanced subclinical atherosclerosis. 2012 , 20, 414-20	6
164	Do cardiovascular disease risk prediction tools need to be updated in Europe?. 2012 , 7, 95	
163	The prevalence and management of cardiovascular risk factors in immigrant groups in Switzerland. 2012 , 57, 63-77	6
162	Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways. 2013 , 6, 52	7
161	Economic efficiency of primary care for CVD prevention and treatment in Eastern European countries. 2013 , 13, 75	3
160	Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. 2013 , 12, 103	3
159	Aldosterone levels and inflammatory stimulation in essential hypertensive patients. 2013 , 27, 535-8	7
158	Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. 2013 , 20, 686-91	28
157	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. 2013 , 20, 678-85	47
156	The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. 2013 , 15, 513-22	4
155	Chapter 5: Referral to specialists and models of care. 2013 , 3, 112-119	30
154	Hypertension risk assessment in the largest ethnic groups in Jordan. 2013 , 15, 43-8	11
153	Prevention of coronary artery disease: recent advances in the management of hypertension. 2013 , 15, 311	4
152	The NAILED stroke risk factor trial (nurse based age independent intervention to limit evolution of disease after stroke): study protocol for a randomized controlled trial. 2013 , 14, 5	11
151	Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. 2013 , 3, 91-111	32
150	Use and indications of cholestyramine and bile acid sequestrants. 2013 , 8, 205-10	54

149	PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats. 2013 , 169, 1510-24	23
148	Enhanced external counterpulsation in patients with refractory angina pectoris: a pilot study with six months follow-up regarding physical capacity and health-related quality of life. 2013 , 12, 437-45	13
147	Protocol for a qualitative study on promoting dietary change and positive food choices for poor people with low income who experience cardiovascular disease in Pakistan. 2013 , 3, e004176	4
146	Is it worth offering cardiovascular disease prevention to the elderly?. 2013 , 20, 121-6	9
145	Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a randomized controlled trial in young adults. 2013 , 2, e000283	22
144	Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. 2013 , 10, 99-114	5
143	Population-level changes to promote cardiovascular health. 2013 , 20, 409-21	76
142	Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. 2013 , 20, 1080-7	14
141	Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. 2013 , 28, 554-60	38
140	Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. 2013 , 20, 40-53	24
139	Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. 2013 , 20, 817-26	95
138	Do obesity and parental history of myocardial infarction improve cardiovascular risk prediction?. 2013 , 20, 793-9	5
137	Depression, anxiety, and risk factor control in patients after hospitalization for coronary heart disease: the EUROASPIRE III Study. 2013 , 20, 331-40	62
136	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. 2013 , 9, 617-70	57
135	Identification and determination of synthetic pharmaceuticals as adulterants in eight common herbal weight loss supplements. 2014 , 16, e15344	36
134	Comparison of three troponins as predictors of future cardiovascular events--prospective results from the FINRISK and BiomaCaRE studies. 2014 , 9, e90063	47
133	Gender difference in long-term prognosis among patients with cardiovascular disease. 2014 , 21, 81-9	9
132	Cardiovascular risk profile of high school students: a cross-sectional study. 2014 , 33, 525-34	5

131	Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea. 2014 , 14, 100	14
130	High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy. 2014 , 7, 955-964	8
129	Insomnia symptoms and subsequent cardiovascular medication: a register-linked follow-up study among middle-aged employees. 2014 , 23, 281-9	19
128	The impact of modern noninvasive cardiac imaging on coronary intervention rates. 2014 , 27, 50-7	3
127	Of heart and kidney: a complicated love story. 2014 , 21, 840-6	9
126	Carotid artery stenting: second consensus document of the ICCS/ISO-SPREAD joint committee. 2014 , 38, 77-93	8
125	Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries. 2014 , 65, 919-26	23
124	Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the REasons for Geographic and Racial Differences in Stroke Study). 2014 , 113, 1933-40	79
123	Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zucker rats. 2014 , 6, 10	4
122	Are lower urinary tract symptoms in men associated with cardiovascular diseases in a primary care population: a registry study. 2014 , 15, 9	8
121	Risk factors for coronary heart disease and survival after myocardial infarction. 2014 , 21, 576-83	14
120	Cardiac rehabilitation and outcome in stable outpatients with recent myocardial infarction. 2014 , 95, 322-9	13
119	Cardiovascular risk profile of high school students: A cross-sectional study. 2014 , 33, 525-534	4
118	Evolving biomarkers improve prediction of long-term mortality in patients with stable coronary artery disease: the BIO-VILCAD score. 2014 , 276, 184-94	19
117	Exercise and competitive sports in patients with an implantable cardioverter-defibrillator. 2014 , 35, 3097-102	32
116	[ENT surgery in patients with anticoagulants and platelet aggregation inhibitors]. 2014 , 62, 350-7	4
115	Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. 2014 , 8, 86-93	31
114	The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study. <i>Cor Et Vasa</i> , 2014 , 56, e91-e97	0.3 11

113	Implementation of telephone-based secondary preventive intervention after stroke and transient ischemic attack - participation rate, reasons for nonparticipation and one-year mortality. 2014 , 4, 28-39	7
112	The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. 2015 , 34, 314-322	1
111	Association of C-Reactive Protein and Metabolic Disorder in a Chinese Population. 2015 , 12, 8228-42	10
110	Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece. 2015 , 6, 199-209	3
109	Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). 2015 , 5, e008017	18
108	Use of implantable cardioverter-defibrillators in athletes: A systematic review. 2015 , 34, 411-419	1
107	Athletes with Implantable Cardioverter Defibrillators. 2015 , 34, 473-87	5
106	Assessment of diet quality improves the classification ability of cardiovascular risk score in predicting future events: The 10-year follow-up of the ATTICA study (2002-2012). 2015 , 22, 1488-98	15
105	Use of implantable cardioverter-defibrillators in athletes: A systematic review. 2015 , 34, 411-9	1
104	Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population. 2015 , 22, 1018-26	43
103	Vegetable intake is associated with lower Frammingham risk scores in Korean men: Korea National Health and Nutrition Survey 2007-2009. 2016 , 10, 89-98	2
102	The Clinical Link between Type D Personality and Diabetes. 2016 , 7, 113	28
101	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. 2016 , 23, 2007-2018	96
100	Fibrates for primary prevention of cardiovascular disease events. 2016 , 11, CD009753	52
99	Associations of proteins relevant to MAPK signaling pathway (p38MAPK-1,HIF-1 and HO-1) with coronary lesion characteristics and prognosis of peri-menopausal women. 2016 , 15, 187	6
98	Carotid Intima-Media Thickness as a Cardiovascular Risk Factor and Imaging Pathway of Atherosclerosis. 2016 , 15, 152-160	13
97	Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. 2016 , 17, 110	11
96	Smoking Cessation After Acute Myocardial Infarction in Relation to Depression and Personality Factors. 2016 , 23, 234-42	5

95	The changes of secondary prevention practice in Czech post-stroke patients between 2007 and 2012/13. <i>Cor Et Vasa</i> , 2016 , 58, e367-e373	0.3	1
94	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular		445
93	Effects of a computerized decision support system in improving pharmacological management in high-risk cardiovascular patients: A cluster-randomized open-label controlled trial. 2016 , 22, 232-47		6
92	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. 2016 , 23, 636-48		549
91	Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial. 2016 , 32, 477-82		12
90	Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. 2016 , 72, 349-57		11
89	Educational level and risk profile and risk control in patients with coronary heart disease. 2016 , 23, 881-90		20
88	Failure to control hypercholesterolaemia in the Irish adult population: cross-sectional analysis of the baseline wave of The Irish Longitudinal Study on Ageing (TILDA). 2017 , 186, 1009-1017		6
87	The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study. 2017 , 263, 219-226		12
86	Low HDL-cholesterol among HIV-1 infected and HIV-1 uninfected individuals in Nairobi, Kenya. 2017 , 16, 110		11
85	Defining Low Disease Activity in Systemic Lupus Erythematosus. 2017 , 69, 997-1003		45
84	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. 2017 , 47, 555-643		44
83	Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study. 2017 , 7, 020702		7
82	Secondary prevention care and effect: Total and low-density lipoprotein cholesterol levels and lipid-lowering drug use in women and men after incident myocardial infarction - The Tromsø Study 1994-2016. 2018 , 17, 563-570		3
81	How to decrease cardiovascular risk factors in people with multiple sclerosis. 2018 , 47, 11-17		
80	Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. 2018 , 2, 158-164		668
79	Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. 2018 , 12, 409-416		23
78	Cómo disminuir factores de riesgo cardiovascular en personas con esclerosis múltiple. 2018 , 47, 11-17		

77	Association of depression and anxiety with cardiovascular co-morbidity in a primary care population in Latvia: a cross-sectional study. 2018 , 18, 328	10
76	Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease. 2018 , 8, e018524	17
75	The Effect of ACE I/D Polymorphisms Alone and With Concomitant Risk Factors on Coronary Artery Disease. 2018 , 24, 157-163	17
74	Association of FV G1691A Polymorphism but not A4070G With Coronary Artery Disease. 2018 , 24, 330-337	1
73	Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. 2018 , 18, 209	12
72	Total flavonoids from <i>Ampelopsis megalophylla</i> suppress proliferation of vascular smooth muscle cells in vivo and in vitro. 2018 , 53,	2
71	Potential gains in life expectancy by eliminating deaths from cardiovascular diseases and diabetes mellitus in the working life ages among Slovak population. 2018 , 8, 16	3
70	Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration. 2018 , 30, 188-192	2
69	Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration. 2018 , 30, 188-192	1
68	Natural approaches in metabolic syndrome management. 2018 , 14, 422-441	83
67	Vegetables. 2018 , 173-229	
66	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. 2019 , 105, 42-48	22
65	Self-Care Adherence And Barriers To Good Glycaemic Control In Nepalese Type 2 Diabetes Mellitus Patients: A Hospital-Based Cross-Sectional Study. 2019 , 12, 817-826	7
64	Health, not weight loss, focused programmes versus conventional weight loss programmes for cardiovascular risk factors: a systematic review and meta-analysis. 2019 , 8, 200	6
63	Performance and cardiac evaluation before and after a 3-week training camp for 400-meter sprinters - An observational, non-randomized study. 2019 , 14, e0217856	1
62	Improved unhealthy lifestyle habits in patients with high cardiovascular risk: results from a structured lifestyle programme in primary care. 2019 , 124, 94-104	3
61	Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial. 2019 , 11,	17
60	Statins for primary prevention of cardiovascular disease. 2019 , 367, l5674	25

59	Coronary heart disease diagnosis by artificial neural networks including aortic pulse wave velocity index and clinical parameters. 2019 , 37, 1682-1688	12
58	Motivators and Deterrents to Diet Change in Low Socio-Economic Pakistani Patients With Cardiovascular Disease. 2019 , 6, 2333393619883605	2
57	Inherited primary arrhythmia disorders: cardiac channelopathies and sports activity. 2020 , 45, 142-157	3
56	Carotid Intima-Media Thickness Versus Carotid Plaque Burden for Predicting Cardiovascular Risk. 2020 , 71, 108-111	16
55	Support from next of kin and nurses are significant predictors of long-term adherence to treatment in post-PCI patients. 2020 , 19, 339-350	6
54	Prescription prevalence of low dose aspirin in primary prevention in the Spanish population, trends over time and associated factors. 2020 , 155, 104-111	
53	Association between glutathione peroxidase-3 activity and carotid atherosclerosis in patients with type 2 diabetes mellitus. 2020 , 10, e01773	5
52	Effectiveness of a nurse-led physical activity intervention to decrease cardiovascular disease risk in middle-aged adults: A pilot randomized controlled study. 2020 , 38, 140-148	2
51	Association of Small Dense Low-Density Lipoprotein Cholesterol with Stroke Risk, Severity and Prognosis. 2020 , 27, 1310-1324	7
50	Effects of a short health education intervention on physical activity, arterial stiffness and cardiac autonomic function in individuals with moderate-to-high cardiovascular risk. 2020 , 103, 1856-1863	1
49	Clinical, physical, physiological, and cardiovascular risk patterns of adults with schizophrenia: CORTEX-SP study: Characterization of adults with schizophrenia. 2021 , 295, 113580	0
48	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2021 , 42, 1289-1367	920
47	Prognostic significance of BMI after PCI treatment in ST-elevation myocardial infarction: a cohort study from the Swedish Coronary Angiography and Angioplasty Registry. 2021 , 8,	1
46	Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2021 , 74, 544.e1-544.e73	1
45	Fragmented QRS formation may be associated with increased carotid intima-media thickness in patients with end-stage renal disease.	
44	Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach. 2021 , 9,	3
43	Prognostic significance of BMI after PCI treatment in ST-elevation myocardial infarction A cohort study from the Swedish Coronary Angiography and Angioplasty Registry.	
42	ESVM Guideline on peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 1-79	1.9 46

41	5 Conservative treatment for PAD - Risk factor management. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 1-12	1.9	6
40	Let's target screening more effectively. 2010 , 34, 540-541		1
39	Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. 2017 , 8, 47110-47120		20
38	Follow-up of a cardiovascular prevention campaign. 2011 , 19, 190-6		3
37	The "Five Risks algorithm": an easy tool for cardiovascular risk estimation. 2009 , 17, 133-8		1
36	How Does the Stock Market Affect Investor Sentiment? -- Evidence from Antidepressant Usage.		2
35	MedFit App, a Behavior-Changing, Theoretically Informed Mobile App for Patient Self-Management of Cardiovascular Disease: User-Centered Development. 2018 , 2, e8		10
34	Health promotion in the workplace: assessing stress and lifestyle with an intranet tool. 2011 , 13, e88		13
33	An Internet- and mobile-based tailored intervention to enhance maintenance of physical activity after cardiac rehabilitation: short-term results of a randomized controlled trial. 2014 , 16, e77		83
32	The Nurse-Based Age Independent Intervention to Limit Evolution of Disease After Acute Coronary Syndrome (NAILED ACS) Risk Factor Trial: Protocol for a Randomized Controlled Trial. 2014 , 3, e42		10
31	Role of niacin in current clinical practice. 2019 , 110, 79-83		5
30	Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids. 2017 , 66, 363-382		31
29	The standard of secondary prevention of stroke in Czech patients in the EUROASPIRE III Study - Stroke Specific Module. <i>Cor Et Vasa</i> , 2008 , 50, 446-454	0.3	10
28	The usual dosage regimen of statins and adherence to target LDL-cholesterol levels by Czech patients in the secondary prevention of coronary heart disease. <i>Cor Et Vasa</i> , 2009 , 51, 92-96	0.3	1
27	The prevalence of major cardiovascular risk factors in the Czech population in 2006-2009. The Czech post-MONICA study. <i>Cor Et Vasa</i> , 2011 , 53, 220-229	0.3	24
26	(The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech post-MONICA study). <i>Cor Et Vasa</i> , 2020 , 62, 6-16	0.3	5
25	The changes in cardiovascular prevention practice between 1995-2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study. <i>Vnitřní Lekarství</i> , 2018 , 64, 1190-1199	0.3	3
24	Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. <i>World Journal of Gastroenterology</i> , 2012 , 18, 212-24	5.6	41

23	Lipids in liver transplant recipients. <i>World Journal of Gastroenterology</i> , 2016 , 22, 3315-24	5.6	19
22	Association between Metabolic Components and Subclinical Atherosclerosis in Korean Adults. <i>Korean Journal of Family Medicine</i> , 2012 , 33, 229-36	1.7	10
21	Gender-based treatment outcomes in diabetic hypertension. <i>Journal of Postgraduate Medicine</i> , 2008 , 54, 252-8	0.8	4
20	Lumen enlargement of the coronary segments located distal to chronic total occlusions successfully treated with drug-eluting stents at follow-up. <i>EuroIntervention</i> , 2014 , 9, 1181-8	3.1	27
19	The role of social and economic factors in the prevention of cardiovascular disease. <i>Cor Et Vasa</i> , 2008 , 50, 309-312	0.3	
18	What are our chances to reach the new LDL-cholesterol treatment goals in secondary prevention?. <i>Cor Et Vasa</i> , 2009 , 51, 131-135	0.3	
17	Did The Captain only have gout?. <i>Tidsskrift for Den Norske Laegeforening</i> , 2010 , 130, 2476-8	3.5	
16	Regulation of risk factors in patients with ischemic heart disease treated with percutaneous coronary intervention. <i>Srce I Krvni Sudovi</i> , 2011 , 30, 257-263		1
15	Role of Carotid Intima-Media Thickness in the Detection of Subclinical Atherosclerosis. <i>Journal of Cardiology & Current Research</i> , 2015 , 3,	0.1	
14	INTEGRAL EVALUATION OF EFFECTIVENESS OF THE RENEWAL TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE AFTER MYOCARDIUM SURGICAL REVASCULARIZATION. <i>EUREKA Health Sciences</i> , 2017 , 5, 11-16	0.1	1
13	Diabetes and smoking are more important for prognosis of patients with peripheral arterial disease than some genetic polymorphisms. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 229-235	1.9	1
12	Miyokard enfarktine kardiyovaskuler olay giren hastalarda 5HT2C polimorfizminin saptanmasi <i>Pamukkale Medical Journal</i> ,		
11	Prescription prevalence of low dose aspirin in primary prevention in the Spanish population, trends over time and associated factors. <i>Medicina Clinica</i> , 2020 , 155, 104-111	1	
10	A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood.		0
9	Depression, anxiety, perceived stress, and their changes predicted medical adherence over 9 months among patients with coronary heart disease. <i>British Journal of Health Psychology</i> , 2021 , 26, 748-766	8.3	3
8	Ergo-anthropometric assessment. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 940-1; author reply 941-2	6.4	2
7	Development of a patient decision aid for prevention of myocardial infarction in type 2 diabetes - rationale, design and pilot testing. <i>Gms Psycho-social-medicine</i> , 2009 , 6, Doc05		6
6	Cardiovascular disease risk factors among rural Kazakh population. <i>Nagoya Journal of Medical Science</i> , 2012 , 74, 51-61	0.7	5

5	Protocol of a Prospective Cohort Study of Physical Activity in Cardiovascular Outcomes (PACVO) in China: Objective, Design, and Baseline Characteristics.. <i>Journal of Cardiovascular Translational Research</i> , 2022 , 1	3.3	
4	Prevalence of Cardiometabolic Syndrome and its Association With Body Shape Index and A Body Roundness Index Among Type 2 Diabetes Mellitus Patients: A Hospital-Based Cross-Sectional Study in a Ghanaian Population. 2,		o
3	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	o
2	Lifestyle counselling - a long-term commitment based on partnership.. 2022 , 23, 35		
1	A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood. <i>Nature Communications</i> , 2022 , 13,	17.4	3